Teva wins FDA nod for migraine prevention drug

Teva (NYSE:TEVA) last week won FDA approval for its humanized monoclonal antibody, Ajovy, designed to prevent migraines.

The treatment, which blocks the receptor for a protein that is linked to migraine pain, is available in quarterly and monthly-injection options. Amgen‘s (NSDQ:AMGN) competitive once-monthly product won FDA approval earlier this year.

Get the full story at our sister site, Drug Delivery Business News.

 

The post Teva wins FDA nod for migraine prevention drug appeared first on MassDevice.

from MassDevice https://ift.tt/2MGxiAr